Wow!
It matters not to PER
Why?
1) Boys that can access the gene therapy drug will get it
others will use other therapies..
2)The cost $3.2 million will be a stumbling block
3) US clinicians are skeptical re efficacy
4)Sarepta is yet to make a profit from the other exon skipping drug
5)Gene therapy has still got a long way to go before it’s widely accepted
6) All in all PER will continue with its path forward
Other exon skipping drugs will use combination therapies.. eg Atl1102
.
https://finance.yahoo.com/news/sarepta-therapeutics-announces-expanded-us-210200030.html
- Forums
- ASX - By Stock
- FDA approves Sareptas Srp901 for the whole population
Wow!It matters not to PERWhy?1) Boys that can access the gene...
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.1¢ |
Change
-0.006(6.90%) |
Mkt cap ! $73.02M |
Open | High | Low | Value | Volume |
8.7¢ | 8.7¢ | 8.1¢ | $154.2K | 1.820M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 33824 | 8.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.4¢ | 275242 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 33824 | 0.081 |
5 | 18604 | 0.080 |
1 | 100200 | 0.079 |
2 | 121300 | 0.077 |
1 | 130000 | 0.076 |
Price($) | Vol. | No. |
---|---|---|
0.084 | 275242 | 2 |
0.085 | 4326 | 1 |
0.089 | 102263 | 2 |
0.090 | 553175 | 3 |
0.091 | 108000 | 1 |
Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |